HZI researchers developed a bacterial strain that can be used in cancer therapy
Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target tumours and to colonise them. Researchers are aiming to make use of this property for cancer therapy, but they are facing a dilemma:
Salmonella infections are life-threatening. Scientists from the Helmholtz Centre for Infection Research (HZI) in Braunschweig now undertook a successful step towards the clinical application. They developed a Salmonella strain that induces only a harmless infection, but activates the immune system strongly enough to fight the tumours. Their results were published in the journal OncoImmunology.
Cancer diseases are some of the most common causes of death throughout the world, and they are still gaining in significance as the average general population gets older. However, we still do not have a satisfactory therapy for many types of tumours. One extremely promising approach is to involve the immune system in the control of the tumour.
Scientists from the HZI use Salmonella enterica bacteria to activate the immune system to tumours and to trigger an inherent defence reaction. In cancer patients, salmonellae colonise tumour tissue specifically, but the infection can take a life-threatening course. "For this type of tumour therapy, a strain of Salmonella must not only trigger a strong defence reaction of the immune system, but it must also not be too aggressive such that we can keep it in check," says Dr Sebastian Felgner, who is a scientist at the HZI.
The HZI researchers introduced genetic changes into the bacteria step-by-step and tried to find an optimal balance between safety and sufficient immune activation. "We changed numerous properties of the salmonellae, for example a component that eliminates the apparatus of motility and therefore restricts the mobility of the bacteria," says Felgner.
In order to increase the visibility of the bacteria to the immune system, the scientists also addressed certain other molecules in the membrane – which is the outer shell – of the salmonellae. This is where so called lipopolysaccharides consisting of sugar chains and lipid chains are anchored. These molecules reside on the surface of the bacteria and are recognised by the immune system as being foreign.
To hide themselves upon infection, salmonellae have a number of enzymes that cleave lipid chains as soon as they enter the host. "We switched off those cleaving enzymes in our Salmonella strain. As a result, the lipid chains on the surface of the bacteria are preserved in the patients and are quite visible to the immune system," says Felgner.
Following this scheme, the scientists introduced a number of other genetic modifications into their Salmonella strain and investigated the therapeutic effect in mice. In the course of this work, they successfully found a proper balance between attenuation of the bacteria and the intensity of the immune reaction, and even took another hurdle:
"One problem is that humans that have been exposed previously to the bacteria developed immunity against them and may possibly no longer respond to the therapeutic salmonellae," says Dr Siegfried Weiß, the former head of the "Molecular Immunology" department of the HZI, who now works at the Hannover Medical School. "Therefore, a therapeutic strain must be able to overcome this inherent protection of the body, since salmonella infections are rather common, especially in countries with poor hygienic conditions where large parts of the population are immune."
The numerous modifications introduced by the HZI researchers have now resulted in a Salmonella strain that mobilises the inherent defence even in mice that are immune to salmonellae. "Even tumours that used to be resistant to the strain are now eliminated by the immune system," says Weiß.
The research is being done in close cooperation with the "Infection Biology of Salmonella" young investigator group of Prof Marc Erhardt, who recently joined the Humboldt University in Berlin. A patent for the newly developed Salmonella strain has been filed. "Our strain is safe and at the same time effective enough for tumour therapy," says Sebastian Felgner. "The next step towards therapeutic application would be to test the strain in clinical studies in cooperation with industrial partners and to check its suitability for clinical application."
Sebastian Felgner, Dino Kocijancic, Michael Frahm, Ulrike Heise, Manfred Rohde, Kurt Zimmermann, Christine Falk, Marc Erhardt, and Siegfried Weiss: Engineered Salmonella enterica serovar Typhimurium overcomes limitations of anti-bacterial immunity in bacteria-mediated tumor therapy. OncoImmunology, 2017, DOI: 10.1080/2162402X.2017.1382791
The press release and a picture are also available on our website: https://www.helmholtz-hzi.de/en/news_events/news/view/article/complete/salmonell...
Helmholtz Centre for Infection Research:
Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, are engaged in the study of different mechanisms of infection and of the body’s response to infection. Helping to improve the scientific community’s understanding of a given bacterium’s or virus’ pathogenicity is key to developing effective new treatments and vaccines. http://www.helmholtz-hzi.de/en
Helmholtz Centre for Infection Research
Press and Communications
Phone: +49 531 6181-1404
Susanne Thiele | Helmholtz-Zentrum für Infektionsforschung
New sensor detects rare metals used in smartphones
24.04.2019 | Penn State
Controlling instabilities gives closer look at chemistry from hypersonic vehicles
24.04.2019 | University of Illinois College of Engineering
The human eye is particularly sensitive to green, but less sensitive to blue and red. Chemists led by Hubert Huppertz at the University of Innsbruck have now developed a new red phosphor whose light is well perceived by the eye. This increases the light yield of white LEDs by around one sixth, which can significantly improve the energy efficiency of lighting systems.
Light emitting diodes or LEDs are only able to produce light of a certain colour. However, white light can be created using different colour mixing processes.
Researchers led by Francesca Ferlaino from the University of Innsbruck and the Austrian Academy of Sciences report in Physical Review X on the observation of supersolid behavior in dipolar quantum gases of erbium and dysprosium. In the dysprosium gas these properties are unprecedentedly long-lived. This sets the stage for future investigations into the nature of this exotic phase of matter.
Supersolidity is a paradoxical state where the matter is both crystallized and superfluid. Predicted 50 years ago, such a counter-intuitive phase, featuring...
A stellar flare 10 times more powerful than anything seen on our sun has burst from an ultracool star almost the same size as Jupiter
A localization phenomenon boosts the accuracy of solving quantum many-body problems with quantum computers which are otherwise challenging for conventional computers. This brings such digital quantum simulation within reach on quantum devices available today.
Quantum computers promise to solve certain computational problems exponentially faster than any classical machine. “A particularly promising application is the...
The technology could revolutionize how information travels through data centers and artificial intelligence networks
Engineers at the University of California, Berkeley have built a new photonic switch that can control the direction of light passing through optical fibers...
17.04.2019 | Event News
15.04.2019 | Event News
09.04.2019 | Event News
24.04.2019 | Life Sciences
24.04.2019 | Life Sciences
24.04.2019 | Life Sciences